Related news from
Sun, 08 Nov 2026 21:25:36 +0000	Cencora’s Q3 CY2026 earnings call: our top 5 analyst questions Cencora delivered calendar Q3 2026 results that aligned with market expectations on revenue and topped analyst profit forecasts. Management credited the quarter’s performance to strong growth in specialty pharmaceuticals, driven by recent acquisitions such as OneOncology and the expansion of its management services organization (MSO) platform. CEO Bob Mauch highlighted these investments as central to Cencora’s ability to support pharmaceutical-centric care, noting increased activity in specialty
Thu, 05 Nov 2026 22:12:14 +0000	Does Earnings Beat Change The Bull Case For Cencora (COR)? Cencora reported fiscal Q4 2026 sales of US$88.35b and net income of US$519.4m, with full year earnings rising to US$3.48b, and increased its quarterly dividend to US$0.66 per share payable on 30 November 2026. The sharp shift from a prior year quarterly net loss to profit, combined with a higher dividend and new segment reporting, gives investors clearer visibility into how specialty services and acquisitions such as OneOncology contribute to Cencora's earnings profile. Next, the focus...
Thu, 05 Nov 2026 21:05:39 +0000	Cencora Inc (COR) (Q4 2026) Earnings Call Highlights: Record Fiscal 2026 Results, New ... Cencora Inc (COR) delivered 12% adjusted EPS growth and $3.8 billion in free cash flow for fiscal 2026 while unveiling a two-segment structure and guiding fiscal 2027 adjusted EPS to $19.40--$19.75.
Thu, 05 Nov 2026 07:14:18 +0000	What Cencora (COR) Said on Its Q4 Earnings Call Cencora (NYSE:COR) reported higher fiscal fourth-quarter revenue and adjusted earnings as specialty drug sales and its acquisition of OneOncology contributed to growth. The company also introduced a new reporting structure that separates its specialty operations from its broader pharmaceutical distr
Wed, 04 Nov 2026 18:48:22 +0000	Cencora (COR) Q4 2026 Earnings Call Transcript Specialty biologics now drive over half of U.S. pharmaceutical spending.
Wed, 04 Nov 2026 18:34:15 +0000	Cencora, Inc. Q4 2026 Earnings Call Summary Moby summary of Cencora, Inc.'s Q4 2026 earnings call
Wed, 04 Nov 2026 17:53:00 +0000	Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins Expand COR's Q4 earnings and revenues beat estimates as specialty drug demand fuels growth and margins expand. The company raises its fiscal 2027 outlook.
Wed, 04 Nov 2026 13:30:06 +0000	Cencora (COR) Reports Q4 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Wed, 04 Nov 2026 12:00:36 +0000	Cencora’s (NYSE:COR) Q3 CY2026 earnings results: revenue in line with expectations Healthcare distributor Cencora (NYSE:COR) met Wall Street’s revenue expectations in calendar Q3 2026 (fiscal Q4 2026), with revenue up 5.5% year on year to $88.35 billion. Its non-GAAP profit of $4.66 per share was 1.9% above analysts’ consensus estimates.
Wed, 04 Nov 2026 11:51:04 +0000	Cencora: Fiscal Q4 Earnings Snapshot (COR) on Wednesday reported fiscal fourth-quarter earnings of $519.The Conshohocken, Pennsylvania-based company said it had net income of $2.
Wed, 04 Nov 2026 11:50:01 +0000	Cencora (COR) Surpasses Q4 Earnings and Revenue Estimates Cencora (COR) delivered earnings and revenue surprises of +2.19% and +0.22%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Wed, 04 Nov 2026 11:35:00 +0000	Cencora Reports Fiscal 2026 Fourth Quarter and Fiscal Year End Results CONSHOHOCKEN, Pa., November 04, 2026--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2026 fourth quarter ended September 30, 2026, revenue increased 5.5 percent to $88.4 billion. Revenue increased 5.0 percent to $337.4 billion for fiscal year 2026. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.71 for the fourth quarter of fiscal 2026, compared to $(1.75) in the prior year quarter. Adjusted diluted EPS, which is a n
Wed, 04 Nov 2026 11:35:00 +0000	Cencora Announces New Organizational and Reporting Structure to Enhance Visibility and Focus CONSHOHOCKEN, Pa., November 04, 2026--Cencora, Inc. (NYSE: COR) today announced that it is realigning its corporate and reporting structure to strengthen execution and visibility.
Thu, 05 Nov 2026 21:24:02 +0000	Drug Wholesalers Go Three-For-Three In Earnings Beats, But Only Two Stocks Pop Drug distributors went three-for-three, with Cardinal Health putting up the last fall-quarter beat on Thursday, following the examples set by McKesson and Cencora.
Fri, 06 Nov 2026 23:26:15 +0000	Is McKesson Stock Increasing Your Market Risk? For questions about this article or underlying research, email help@trefis.com.
Fri, 06 Nov 2026 12:31:00 +0000	3 Stocks in Focus That Hiked Dividends Amid Ongoing Market Volatility BDX, COR and UNF recently hiked dividends, offering investors steady income opportunities as market volatility, inflation and economic uncertainty persist.
Thu, 05 Nov 2026 21:17:27 +0000	The Biggest Drug Wholesaler Just Crushed Earnings Views — Here's What To Know McKesson stock rose Thursday after the drug wholesaler topped fiscal second-quarter views and hiked its earnings guide.
Thu, 05 Nov 2026 16:39:19 +0000	What Just Happened To Medline Stock? For questions about this article or underlying research, email help@trefis.com.
Tue, 03 Nov 2026 11:13:00 +0000	Mettler-Toledo's Q3 Earnings on Deck: What's in Store for the Stock? MTD's Q3'26 results are expected to benefit from improving markets, automation demand, acquisitions and growth across key regions.
Thu, 05 Nov 2026 16:25:02 +0000	Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027? Amgen's growth engine and Pfizer's value appeal pull in opposite directions, and the valuation gap between them is wider than many expect.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!